Switch theme
Sign up to access all valuation multiples
Medincell SA is a technology-based pharmaceutical firm, aims to optimise the efficiency of medical treatments and make them accessible geographically. The company's product portfolio uses BEPO-patented technology to develop controlled, long-acting injectable medical treatments for a number of therapeutic fields. The firm has a single operating segment: ongoing research and development on processes that use biodegradable polymers to enable the controlled and prolonged release of the active principles of drugs into the human body and animals by means of injection.
2003
143
LTM Revenue $21.6M
LTM EBITDA $1.1M
$634M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Medincell has a last 12-month revenue (LTM) of $21.6M and a last 12-month EBITDA of $1.1M.
In the most recent fiscal year, Medincell achieved revenue of $10.3M and an EBITDA of -$20.9M.
Medincell expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Medincell valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $21.6M | XXX | $10.3M | XXX | XXX | XXX |
| Gross Profit | $21.6M | XXX | $10.3M | XXX | XXX | XXX |
| Gross Margin | 100% | XXX | 100% | XXX | XXX | XXX |
| EBITDA | $1.1M | XXX | -$20.9M | XXX | XXX | XXX |
| EBITDA Margin | 5% | XXX | -203% | XXX | XXX | XXX |
| EBIT | -$8.4M | XXX | -$23.6M | XXX | XXX | XXX |
| EBIT Margin | -39% | XXX | -229% | XXX | XXX | XXX |
| Net Profit | -$24.5M | XXX | -$28.1M | XXX | XXX | XXX |
| Net Margin | -114% | XXX | -273% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | $41.1M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Medincell's stock price is EUR 16 (or $18).
Medincell has current market cap of EUR 543M (or $610M), and EV of EUR 564M (or $634M).
See Medincell trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $634M | $610M | XXX | XXX | XXX | XXX | $-0.88 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Medincell has market cap of $610M and EV of $634M.
Medincell's trades at 38.4x EV/Revenue multiple, and -117.4x EV/EBITDA.
Equity research analysts estimate Medincell's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Medincell has a P/E ratio of -24.9x.
See valuation multiples for Medincell and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $610M | XXX | $610M | XXX | XXX | XXX |
| EV (current) | $634M | XXX | $634M | XXX | XXX | XXX |
| EV/Revenue | 29.3x | XXX | 38.4x | XXX | XXX | XXX |
| EV/EBITDA | 581.6x | XXX | -117.4x | XXX | XXX | XXX |
| EV/EBIT | -75.7x | XXX | -49.0x | XXX | XXX | XXX |
| EV/Gross Profit | 29.3x | XXX | n/a | XXX | XXX | XXX |
| P/E | -24.9x | XXX | -21.8x | XXX | XXX | XXX |
| EV/FCF | 34.0x | XXX | 43.8x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialMedincell's last 12 month revenue growth is 117%
Medincell's revenue per employee in the last FY averaged $0.1M, while opex per employee averaged $0.2M for the same period.
Medincell's rule of 40 is -103% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Medincell's rule of X is 296% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Medincell and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 117% | XXX | 122% | XXX | XXX | XXX |
| EBITDA Margin | 5% | XXX | -33% | XXX | XXX | XXX |
| EBITDA Growth | 1219% | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | -103% | XXX | 84% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 296% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.1M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.2M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | 6% | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 230% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 329% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Medincell acquired XXX companies to date.
Last acquisition by Medincell was XXXXXXXX, XXXXX XXXXX XXXXXX . Medincell acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Medincell founded? | Medincell was founded in 2003. |
| Where is Medincell headquartered? | Medincell is headquartered in France. |
| How many employees does Medincell have? | As of today, Medincell has 143 employees. |
| Is Medincell publicy listed? | Yes, Medincell is a public company listed on PAR. |
| What is the stock symbol of Medincell? | Medincell trades under MEDCL ticker. |
| When did Medincell go public? | Medincell went public in 2018. |
| Who are competitors of Medincell? | Similar companies to Medincell include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Medincell? | Medincell's current market cap is $610M |
| What is the current revenue of Medincell? | Medincell's last 12 months revenue is $21.6M. |
| What is the current revenue growth of Medincell? | Medincell revenue growth (NTM/LTM) is 117%. |
| What is the current EV/Revenue multiple of Medincell? | Current revenue multiple of Medincell is 29.3x. |
| Is Medincell profitable? | Yes, Medincell is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Medincell? | Medincell's last 12 months EBITDA is $1.1M. |
| What is Medincell's EBITDA margin? | Medincell's last 12 months EBITDA margin is 5%. |
| What is the current EV/EBITDA multiple of Medincell? | Current EBITDA multiple of Medincell is 581.6x. |
| What is the current FCF of Medincell? | Medincell's last 12 months FCF is $18.6M. |
| What is Medincell's FCF margin? | Medincell's last 12 months FCF margin is 86%. |
| What is the current EV/FCF multiple of Medincell? | Current FCF multiple of Medincell is 34.0x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
